Press Releases

Date Title and Summary  
Toggle Summary Geron Corporation to Present at UBS Global Generic & Specialty Pharmaceuticals Conference
Menlo Park, CA – May 7, 2007 –– Geron Corporation (Nasdaq: GERN) will be presenting an update of the company’s product development programs on Tuesday, May 8, 2007, at the UBS Global Generic & Specialty Pharmaceuticals Conference at 9:00 a.m. Eastern Time in New York City.
Toggle Summary Geron Corporation Reports 2007 First Quarter Financial Results
Menlo Park, Calif. – April 27, 2007 – Geron Corporation (Nasdaq: GERN) today reported financial results for the three months ended March 31, 2007. For the first quarter of 2007, the company reported operating revenues of $916,000 and operating expenses of $17.3 million, compared to $583,000 and
Toggle Summary Telomerase Presentations at the AACR 2007 Annual Meeting
Menlo Park, CA –– April 25, 2007 –– Geron Corporation (Nasdaq: GERN) today referenced multiple presentations on the role of telomerase and telomeres in cancer at this year’s American Association for Cancer Research (AACR) Annual Meeting in Los Angeles.
Toggle Summary Geron and CXR Conclude Collaboration to Develop In Vitro Assays Using hESC-Derived Hepatocytes
MENLO PARK, Calif., and Dundee, Scotland, April 24, 2007 – Geron Corporation (Nasdaq: GERN) and CXR Biosciences Ltd. today announced the conclusion of a research collaboration that focused on the development of human embryonic stem cell (hESC)–derived hepatocytes for use in in vitro assays of drug
Toggle Summary Studies Confirm Proof-of-Principle for Geron´s Human Embryonic Stem Cell (hESC) Derived Hepatocytes
Findings Published in Cloning and Stem Cells Indicate Utility for Predictive Toxicology Tests MENLO PARK, Calif., April 19, 2007 – Geron Corporation (Nasdaq: GERN) announced today that it has developed standardized hepatocytes from human embryonic stem cells (hESCs) that can model human hepatic
Toggle Summary Geron Supports WARF´s Claims to Human Embryonic Stem Cell Patents
MENLO PARK, Calif., Apr. 2, 2007 – Geron Corporation (Nasdaq: GERN) supports the position of the Wisconsin Alumni Research Foundation (WARF) that U.S. patents covering Dr. James Thomson’s pioneering work with human embryonic stem cells were properly granted.
Toggle Summary Geron Corporation Reports Fourth Quarter and Annual 2006 Financial Results and Highlights
Annual 2005, 2004 and 2003 Financial Statement Information Restated to Reflect Change in Warrant Classification as Previously Disclosed MENLO PARK, Calif., Mar. 16, 2007 – Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and year ended December 31, 2006.
Toggle Summary Geron Grants License to Asia Biotech Corporation
Commercial License to Develop and Market Non–Therapeutic Products Using Telomerase Activators MENLO PARK, Calif., March 12, 2007 – Geron Corporation (Nasdaq: GERN) today announced it has granted an exclusive global license to Asia Biotech Corporation for the development of non–prescription dietary
Toggle Summary Geron to Restate Financial Results of Prior Periods
No Impact on Reported Revenues, Operating Expenses, Total Assets or Cash Position MENLO PARK, Calif., March 9, 2007 – Geron Corporation (Nasdaq: GERN) today announced that the company will restate its financial statements for the 2005, 2004 and 2003 fiscal years as well as its quarterly financial
Toggle Summary Geron Corporation Announces Exercise Of Warrants for $15.0 Million of Proceeds
MENLO PARK, Calif., Feb. 27, 2007 – Geron Corporation (Nasdaq: GERN) today announced the exercise of warrants to purchase 1,875,000 shares of common stock at $8.00 per share for gross proceeds of $15.0 million. The exercised warrants were issued to institutional investors in connection with the